Cysticlean® a highly pac standardized content in the prevention of recurrent urinary tract infections: an observational, prospective cohort study
1 Urodynamics Unit, Hospital Quirón, Avenida de Vicente Blasco Ibañez 14, 46010, Valencia, Spain
2 Urology Department, Consorcio Hospital General Universitario, Valencia, Spain
3 Primary Health Care, Clínica Comarcal Atenea Aldaia, Valencia, Spain
4 Urology Department Hospital de la Malvarrosa, University of Valencia, Valencia, Spain
5 Nephrology Department, Hospital Lluis Alcanyis de Xativa, Valencia, Spain
Citation and License
BMC Urology 2013, 13:28 doi:10.1186/1471-2490-13-28Published: 5 June 2013
The present study was aimed at determining the prophylactic efficacy of American cranberry (AC) extract (Cysticlean®) in women with recurrent symptomatic postcoital urinary tract infections (PCUTI), non-consumer of AC extract in the past 3 months before inclusion, and to determine changes in their quality of life (QoL).
This was a single center, observational, prospective study in a total of 20 women (mean age 35.2 years; 50.0% were married). Patients were followed up for 3 and 6 months during treatment.
The number of PCUTIs in the previous 3 months prior to start the treatment with Cysticlean® was 2.8±1.3 and it was reduced to 0.2±0.5 at Month 6 (P<0.0001), which represent a 93% improvement. At baseline, the mean score on the VAS scale (range from 0 to 100) for assessing the QoL was 62.4±19.1, increasing to 78.2±12.4 at Month 6 (P=0.0002), which represents a 20% improvement. All patients had an infection with positive urine culture at baseline, after 6 months there were only 3 symptomatic infections (P<0.001). The most common bacterium was Escherichia coli.
Prophylaxis with American cranberry extract (Cysticlean®) could be an alternative to classical therapies with antibiotics. Further studies are needed to confirm results obtained in this pilot study.